Xylonix and Invitrocue form strategic clinical alliance to validate new method for combating IL-6 pathologies
Xylonix and Invitrocue form strategic clinical alliance to validate new method for combating IL-6 pathologies
Press Releases
Invitrocue and Angsana partner with Averywell to advance early lung cancer detection across Asia
Invitrocue and Angsana partner with Averywell to advance early lung cancer detection across Asia
Invitrocue announces merger with Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories
Invitrocue announces merger with Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories
Strategic partnership & Financial advisor appointment
Strategic partnership & Financial advisor appointment
Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean
Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean
Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology
Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology
Operational Updates – February 2024
Operational Updates – February 2024
Operational Updates – October 2023
Operational Updates – October 2023
Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit
Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit
Singapore’s Ministry of Health grant license approval for commercial use for Onco-PDO™ – Personalized Cancer Drug Screening
Singapore’s Ministry of Health grant license approval for commercial use for Onco-PDO™ – Personalized Cancer Drug Screening